Brought to you by 
Ironwood gets exclusive US rights to AZ/Ardea's gout therapy lesinurad; deal ends
31 Jul 2019
Executive Summary
AstraZeneca PLC and its Ardea Biosciences Inc. division granted Ironwood Pharmaceuticals Inc. exclusive US rights to all products containing lesinurad for hyperuricemia associated with uncontrolled gout.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ironwood gets exclusive US rights to AZ/Ardea's gout therapy lesinurad; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice